{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T22:34:45Z","timestamp":1774305285032,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003958","name":"Stichting voor de Technische Wetenschappen","doi-asserted-by":"publisher","award":["19060"],"award-info":[{"award-number":["19060"]}],"id":[{"id":"10.13039\/501100003958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13318-025-00951-6","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:08:15Z","timestamp":1749755295000},"page":"341-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dose, Kidney Function, and a Drug\u2013Excipient Interaction Impair Mycophenolate Mofetil Prodrug Activation in Kidney Transplant Recipients"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1370-0041","authenticated-orcid":false,"given":"Fleur B.","family":"Nijdam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-1522","authenticated-orcid":false,"given":"Marieke A. J.","family":"Hof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0011-115X","authenticated-orcid":false,"given":"Daan","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3246-3192","authenticated-orcid":false,"given":"Tim J.","family":"Knobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9087-606X","authenticated-orcid":false,"given":"G\u00e9rard","family":"Hopfgartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3356-6791","authenticated-orcid":false,"given":"Stephan J. L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eelko","family":"Hak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-1694","authenticated-orcid":false,"given":"Frank","family":"Klont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"TransplantLines Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"951_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02834.x","author":"KU Eckardt","year":"2009","unstructured":"Eckardt KU, Kasiske BL, Zeier MG. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02834.x.","journal-title":"Am J Transplant"},{"key":"951_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007746.pub2","author":"M Wagner","year":"2015","unstructured":"Wagner M, Earley AK, Webster AC, Schmid CH, Balk EM, Uhlig K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD007746.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"951_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12554","author":"T Van Gelder","year":"2015","unstructured":"Van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Intl. 2015. https:\/\/doi.org\/10.1111\/tri.12554.","journal-title":"Transpl Intl."},{"key":"951_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000871","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, et al. Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit. 2021. https:\/\/doi.org\/10.1097\/FTD.0000000000000871.","journal-title":"Ther Drug Monit"},{"key":"951_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/45.3.419","author":"E Sch\u00fctz","year":"1999","unstructured":"Sch\u00fctz E, Skipkova M, Armstrong VW, Wieland E, Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem. 1999. https:\/\/doi.org\/10.1093\/clinchem\/45.3.419.","journal-title":"Clin Chem"},{"key":"951_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702399","author":"M Shipkova","year":"1999","unstructured":"Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol. 1999. https:\/\/doi.org\/10.1038\/sj.bjp.0702399.","journal-title":"Br J Pharmacol"},{"key":"951_CR7","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834060-00002\/METRICS","author":"RES Bullingham","year":"1998","unstructured":"Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998. https:\/\/doi.org\/10.2165\/00003088-199834060-00002\/METRICS.","journal-title":"Clin Pharmacokinet"},{"key":"951_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12100942","author":"F Klont","year":"2022","unstructured":"Klont F, Sosnowski P, Kremer D, et al. Assessing the potential of untargeted SWATH mass spectrometry-based metabolomics to differentiate closely related exposures in observational studies. Metabolites. 2022. https:\/\/doi.org\/10.3390\/metabo12100942.","journal-title":"Metabolites"},{"key":"951_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1194","author":"SC Laizure","year":"2013","unstructured":"Laizure SC, Herring V, Hu Z, et al. The role of human carboxylesterases in drug metabolism: Have we overlooked their importance? Pharmacotherapy. 2013. https:\/\/doi.org\/10.1002\/phar.1194.","journal-title":"Pharmacotherapy"},{"key":"951_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093819","author":"C Zhang","year":"2014","unstructured":"Zhang C, Xu Y, Zhong Q, Witbrodt K, Parker RB. In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2. PLoS ONE. 2014. https:\/\/doi.org\/10.1371\/journal.pone.0093819.","journal-title":"PLoS ONE"},{"key":"951_CR11","doi-asserted-by":"publisher","DOI":"10.1039\/D3AN01874A","author":"F Klont","year":"2024","unstructured":"Klont F, Nijdam FB, Bakker SJL, Keski-Rahkonen P, Hopfgartner G. High-abundance peaks and peak clusters associate with pharmaceutical polymers and excipients in urinary untargeted clinical metabolomics data: exploration of their origin and possible impact on label-free quantification. Analyst. 2024. https:\/\/doi.org\/10.1039\/D3AN01874A.","journal-title":"Analyst"},{"key":"951_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024502","author":"MF Eisenga","year":"2018","unstructured":"Eisenga MF, Gomes-Neto AW, Van Londen M, et al. Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients. BMJ Open. 2018. https:\/\/doi.org\/10.1136\/bmjopen-2018-024502.","journal-title":"BMJ Open"},{"key":"951_CR13","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013050497","author":"E Van den Berg","year":"2014","unstructured":"Van den Berg E, Pasch A, Westendorp WH, et al. Urinary sulfur metabolites associate with a favorable cardiovascular risk profile and survival benefit in renal transplant recipients. J Am Soc Nephrol. 2014. https:\/\/doi.org\/10.1681\/ASN.2013050497.","journal-title":"J Am Soc Nephrol"},{"key":"951_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"key":"951_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2102953","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin c-based equations to estimate GFR without race. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/nejmoa2102953.","journal-title":"N Engl J Med"},{"key":"951_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/J.FCT.2022.113188","author":"F Klont","year":"2022","unstructured":"Klont F, Stepanovi\u0107 S, Kremer D, et al. Untargeted \u2018SWATH\u2019 mass spectrometry-based metabolomics for studying chronic and intermittent exposure to xenobiotics in cohort studies. Food Chem Toxicol. 2022. https:\/\/doi.org\/10.1016\/J.FCT.2022.113188.","journal-title":"Food Chem Toxicol"},{"key":"951_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.201500779","author":"P Partani","year":"2015","unstructured":"Partani P, Verma SM, Monif T. Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: application to a bioequivalence study and metabolite identification. J Sep Sci. 2015. https:\/\/doi.org\/10.1002\/jssc.201500779.","journal-title":"J Sep Sci"},{"key":"951_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/J.JSBMB.2010.04.010","author":"N Krone","year":"2010","unstructured":"Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CHL. Gas chromatography\/mass spectrometry (GC\/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC\/MS\/MS). J Steroid Biochem Mol Biol. 2010. https:\/\/doi.org\/10.1016\/J.JSBMB.2010.04.010.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"951_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200412000-00004","author":"N Picard","year":"2004","unstructured":"Picard N, Cresteil T, Pr\u00e9maud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4\/5. Ther Drug Monit. 2004. https:\/\/doi.org\/10.1097\/00007691-200412000-00004.","journal-title":"Ther Drug Monit"},{"key":"951_CR20","doi-asserted-by":"publisher","DOI":"10.21105\/JOSS.01686","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. J Open Source Softw. 2019. https:\/\/doi.org\/10.21105\/JOSS.01686.","journal-title":"J Open Source Softw."},{"key":"951_CR21","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v034.i02","author":"F Cribari-Neto","year":"2010","unstructured":"Cribari-Neto F, Zeileis A. Beta regression in R. J Stat Softw. 2010. https:\/\/doi.org\/10.18637\/jss.v034.i02.","journal-title":"J Stat Softw"},{"key":"951_CR22","unstructured":"Garofalo S. StepBeta: Stepwise Procedure for Beta, Beta-Binomial and Negative Binomial Regression Models. CRAN. 2022. https:\/\/CRAN.R-project.org\/package=StepBeta. Accessed Jul 2023."},{"key":"951_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.036","author":"T van Gelder","year":"2021","unstructured":"van Gelder T. How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not. Kidney Int. 2021. https:\/\/doi.org\/10.1016\/j.kint.2021.06.036.","journal-title":"Kidney Int"},{"key":"951_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0678-8","author":"RK Verbeeck","year":"2009","unstructured":"Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009. https:\/\/doi.org\/10.1007\/s00228-009-0678-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"951_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-012-0029-x","author":"KHJ Ehinger","year":"2013","unstructured":"Ehinger KHJ, Hansson MJ, Sj\u00f6vall F, et al. Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor\u00ae EL. Clin Drug Invest. 2013. https:\/\/doi.org\/10.1007\/s40261-012-0029-x.","journal-title":"Clin Drug Invest"},{"key":"951_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPS.2022.106123","author":"SG P\u0131nar","year":"2022","unstructured":"P\u0131nar SG, Canp\u0131nar H, Tan \u00c7, \u00c7elebi N. A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation. Eur J Pharm Sci. 2022. https:\/\/doi.org\/10.1016\/J.EJPS.2022.106123.","journal-title":"Eur J Pharm Sci"},{"key":"951_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218224","author":"R Patel","year":"2020","unstructured":"Patel R, Barker J, ElShaer A. Pharmaceutical excipients and drug metabolism: a mini-review. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21218224.","journal-title":"Int J Mol Sci"},{"key":"951_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/S12967-018-1710-5","author":"JJ Karakunnel","year":"2018","unstructured":"Karakunnel JJ, Bui N, Palaniappan L, et al. Reviewing the role of healthy volunteer studies in drug development. J Transl Med. 2018. https:\/\/doi.org\/10.1186\/S12967-018-1710-5.","journal-title":"J Transl Med"},{"key":"951_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.ATG.2014.05.001","author":"M Kussmann","year":"2014","unstructured":"Kussmann M, Kaput J. Translational genomics. Appl Transl Genom. 2014. https:\/\/doi.org\/10.1016\/J.ATG.2014.05.001.","journal-title":"Appl Transl Genom."},{"key":"951_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-016-1094-6","author":"RD Beger","year":"2016","unstructured":"Beger RD, Dunn W, Schmidt MA, et al. Metabolomics enables precision medicine: \u201cA White Paper, Community Perspective.\u201d Metabolomics. 2016. https:\/\/doi.org\/10.1007\/s11306-016-1094-6.","journal-title":"Metabolomics"},{"key":"951_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107191","author":"F Klont","year":"2024","unstructured":"Klont F, Hof MAJ, Nijdam FB, et al. Pharmacometabolomics may be the next stamp in the pharmacogenetic passport. Pharm Res. 2024. https:\/\/doi.org\/10.1016\/j.phrs.2024.107191.","journal-title":"Pharm Res"},{"key":"951_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUDIS.2022.103460","author":"A Palermo","year":"2023","unstructured":"Palermo A. Metabolomics- and systems-biology-guided discovery of metabolite lead compounds and druggable targets. Drug Discov Today. 2023. https:\/\/doi.org\/10.1016\/J.DRUDIS.2022.103460.","journal-title":"Drug Discov Today"},{"key":"951_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/METABO10020051","author":"NP Long","year":"2020","unstructured":"Long NP, Nghi TD, Kang YP, et al. Toward a Standardized Strategy of Clinical Metabolomics for the Advancement of Precision Medicine. Metabolites. 2020. https:\/\/doi.org\/10.3390\/METABO10020051.","journal-title":"Metabolites"},{"key":"951_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE04648","author":"TA Clayton","year":"2006","unstructured":"Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006. https:\/\/doi.org\/10.1038\/NATURE04648.","journal-title":"Nature"},{"key":"951_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.141","author":"SU Yasuda","year":"2008","unstructured":"Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharm Therap. 2008. https:\/\/doi.org\/10.1038\/clpt.2008.141.","journal-title":"Clin Pharm Therap."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00951-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T19:02:41Z","timestamp":1751655761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00951-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00951-6","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"14 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization\u2014FBN, FK; Methodology\u2014FBN, MAJH, FK; Software\u2014N\/A; Validation\u2014FK; Formal Analysis\u2014FBN, MAJH; Investigation\u2014FBN, MAJH, FK; Resources\u2014SJLB, GH, FK, TI; Data Curation\u2014FBN, DK, TJK, FK; Writing-Original Draft Preparation\u2014FBN, FK; Writing-Review and Editing\u2014FBN, MAJH, DK, TJK, GH, SJLB, EH, FK; Visualization\u2014FBN; Supervision\u2014FK; Project Administration\u2014FK; Funding Acquisition\u2014TI, FK. All authors had free and direct access to the data, and all authors have read and agreed to the published version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Both study protocols for the TransplantLines Biobank and Cohort Study (TxL) and the TransplantLines Food and Nutrition Biobank and Cohort Study (TxL-FN) were approved by the Institutional Review Board of the University Medical Center Groningen (METc 2014\/077 and METc 2008\/186 for TxL and TxL-FN, respectively), and adhered to the Declarations of Helsinki and Istanbul.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants gave written informed consent upon enrollment for both the TransplantLines Biobank and Cohort Study and the TransplantLines Food and Nutrition Biobank and Cohort Study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}